| Peter H Bagley, MD | |
|
6 Glen Cove Dr, Rockport, ME 04856-4272 | |
| (207) 301-8542 | |
| (207) 301-5277 |
| Full Name | Peter H Bagley |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 44 Years |
| Location | 6 Glen Cove Dr, Rockport, Maine |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003899683 | NPI | - | NPPES |
| 3068315 | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 73375 (Massachusetts) | Secondary |
| 207RP1001X | Internal Medicine - Pulmonary Disease | MD21833 (Maine) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Penobscot Bay Medical Center | Rockport, ME | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mainehealth | 7517860588 | 2067 |
News Archive
Approximately 8 to 12 million people in the United States alone are suffering from peripheral arterial disease (PAD), a common vascular problem that is caused by narrowing of the arteries as a result of plaque buildup. The plaque accumulation leads to an insufficient blood flow to the body's extremities and increases a person's risk for heart attack and stroke by up to six times. PAD is also one of the most serious complications of diabetes.
ESTEVE announces the recent publication of data from the Phase I clinical trial programme of a novel, highly potent and selective, once-daily, S1RA E-52862, developed by the ESTEVE R&D team, in the British Journal of Clinical Pharmacology.
Patients with myeloma could benefit from ‘designer' drugs in the future after new genome-mapping technology has allowed scientists to identify a full genetic blueprint of the mutations which drive the bone marrow cancer.
An anti-cancer drug could potentially be the first effective treatment for the many thousands of premature births that occur worldwide each year, scientific tests have found.
› Verified 6 days ago
| Entity Name | St Marys Regional Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447226584 PECOS PAC ID: 0042107120 Enrollment ID: O20040303000236 |
News Archive
Approximately 8 to 12 million people in the United States alone are suffering from peripheral arterial disease (PAD), a common vascular problem that is caused by narrowing of the arteries as a result of plaque buildup. The plaque accumulation leads to an insufficient blood flow to the body's extremities and increases a person's risk for heart attack and stroke by up to six times. PAD is also one of the most serious complications of diabetes.
ESTEVE announces the recent publication of data from the Phase I clinical trial programme of a novel, highly potent and selective, once-daily, S1RA E-52862, developed by the ESTEVE R&D team, in the British Journal of Clinical Pharmacology.
Patients with myeloma could benefit from ‘designer' drugs in the future after new genome-mapping technology has allowed scientists to identify a full genetic blueprint of the mutations which drive the bone marrow cancer.
An anti-cancer drug could potentially be the first effective treatment for the many thousands of premature births that occur worldwide each year, scientific tests have found.
› Verified 6 days ago
| Entity Name | Mainehealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790265502 PECOS PAC ID: 7517860588 Enrollment ID: O20040701000166 |
News Archive
Approximately 8 to 12 million people in the United States alone are suffering from peripheral arterial disease (PAD), a common vascular problem that is caused by narrowing of the arteries as a result of plaque buildup. The plaque accumulation leads to an insufficient blood flow to the body's extremities and increases a person's risk for heart attack and stroke by up to six times. PAD is also one of the most serious complications of diabetes.
ESTEVE announces the recent publication of data from the Phase I clinical trial programme of a novel, highly potent and selective, once-daily, S1RA E-52862, developed by the ESTEVE R&D team, in the British Journal of Clinical Pharmacology.
Patients with myeloma could benefit from ‘designer' drugs in the future after new genome-mapping technology has allowed scientists to identify a full genetic blueprint of the mutations which drive the bone marrow cancer.
An anti-cancer drug could potentially be the first effective treatment for the many thousands of premature births that occur worldwide each year, scientific tests have found.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Peter H Bagley, MD 6 Glen Cove Dr, Rockport, ME 04856-4272 Ph: (207) 301-8542 | Peter H Bagley, MD 6 Glen Cove Dr, Rockport, ME 04856-4272 Ph: (207) 301-8542 |
News Archive
Approximately 8 to 12 million people in the United States alone are suffering from peripheral arterial disease (PAD), a common vascular problem that is caused by narrowing of the arteries as a result of plaque buildup. The plaque accumulation leads to an insufficient blood flow to the body's extremities and increases a person's risk for heart attack and stroke by up to six times. PAD is also one of the most serious complications of diabetes.
ESTEVE announces the recent publication of data from the Phase I clinical trial programme of a novel, highly potent and selective, once-daily, S1RA E-52862, developed by the ESTEVE R&D team, in the British Journal of Clinical Pharmacology.
Patients with myeloma could benefit from ‘designer' drugs in the future after new genome-mapping technology has allowed scientists to identify a full genetic blueprint of the mutations which drive the bone marrow cancer.
An anti-cancer drug could potentially be the first effective treatment for the many thousands of premature births that occur worldwide each year, scientific tests have found.
› Verified 6 days ago
Neil D. Smith, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 823 Commercial St, Rockport, ME 04856 Phone: 207-596-6599 | |
Mira Regina Olson, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 4 Glen Cove Dr Ste 10, Rockport, ME 04856 Phone: 207-301-5970 Fax: 207-301-5310 | |
Dr. Donald J Weaver, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 4 Glen Cove Dr, Ste 104, Rockport, ME 04856 Phone: 207-594-7705 Fax: 207-594-0543 | |
Eric Elton, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 4 Glen Cove Dr Ste 10, Rockport, ME 04856 Phone: 207-301-5790 Fax: 207-301-5310 | |
Victoria Hoch, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 6 Glen Cove Dr, Rockport, ME 04856 Phone: 207-301-8000 | |
Andrew E. Filderman, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 4 Glen Cove Dr Ste 107, Rockport, ME 04856 Phone: 207-594-4244 |